1. Home
  2. ANL vs DCH Comparison

ANL vs DCH Comparison

Compare ANL & DCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Logo Dauch Corporation Common Stock

DCH

Dauch Corporation Common Stock

N/A

Current Price

$4.72

Market Cap

1.1B

ML Signal

N/A

Company Overview

Basic Information
Metric
ANL
DCH
Founded
2004
1994
Country
Singapore
United States
Employees
N/A
20000
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.1B
IPO Year
2022
1998

Fundamental Metrics

Financial Performance
Metric
ANL
DCH
Price
$10.80
$4.72
Analyst Decision
Strong Buy
Buy
Analyst Count
7
13
Target Price
★ $29.50
$7.58
AVG Volume (30 Days)
268.1K
★ 4.9M
Earning Date
08-14-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $5,836,700,000.00
Revenue This Year
$243.83
$85.07
Revenue Next Year
N/A
$2.28
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.88
$4.38
52 Week High
$17.25
$8.75

Technical Indicators

Market Signals
Indicator
ANL
DCH
Relative Strength Index (RSI) 46.74 45.07
Support Level $8.95 $4.44
Resistance Level $11.90 $5.12
Average True Range (ATR) 0.99 0.27
MACD 0.25 0.04
Stochastic Oscillator 72.55 44.22

Price Performance

Historical Comparison
ANL
DCH

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About DCH Dauch Corporation Common Stock

Dauch Corp is a world-wide Tier 1 Automotive Supplier, Dauch designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles.

Share on Social Networks: